Grade II gliomas are morphologically and clinically heterogeneous tumors for which histopathological typing remains the major tool for clinical classification. To what extent the major histological subtypes (astrocytic, oligodendroglial, oligoastrocytic and ependymal tumors) constitute is largely unresolved. Morphological classification can often be ambiguous and would be facilitated by specific subtype markers. Gene expression profiling is becoming an established method to characterize different types of cancers, and it has been used extensively for glioblastoma analysis and for low-grade glioma to glioblastoma comparison. However, few studies of low-grade oligodendrogliomas and ependymomas have been reported. Using oligonucleotide-based microarray analysis, we compared the transcriptional profiles of grade II oligodendrogliomas and grade II ependymomas (two types of grade II gliomas). An essential initial step toward more objective tumor classification is the establishment of taxonomy for tumors based on their gene expression profiles. We aimed to identify expression profiles that differentiate these two types of grade II gliomas. After comparing the expression signature of a tumor to that of normal tissue, differentially expressed genes were used to perform hierarchal clustering, principal component analysis and prediction analysis. Hierarchal clustering and principal component analysis divided nine different tumor tissue samples and four normal brain tissue samples into categories that corresponded well with clinical pathology analysis, grade II oligodendrogliomas, grade II ependymomas and normal tissues. By using expression data from the most informative gene clusters, we constructed a tumor-clustering model. Class prediction using nearest shrunken centroid analysis with cross-validation identified 53 differentially expressed genes between the two types of grade II gliomas.
INTRODUCTION
Oligodendrogliomas and ependymomas are rare primary brain tumors accounting for 3.2 and 2.3%, respectively, of *Corresponding author. Email: gaochunfang2010@163.com. Tel: +86-379-64169001. Fax: +86-379-64169112. #These authors contributed equally to this work. all primary central nervous system (CNS) neoplasms (Surawicz et al., 1999) . According to the 2007 World Health Organization (WHO) classification system, the most commonly accepted grading system for brain tumors, surgical specimens, should be assessed for atypical cells, mitoses, endothelial proliferation, and necrosis. Oligoastrocytomas and ependymomas are included in the four main histological types of grade II glioma (Louis et al., 2007) . The peak incidence of these tumors is in the fourth and fifth decades of life, and they are comparatively rare in children, in whom they constitute 1 to 2% of all CNS tumors (Goussia et al., 2001) . Most oligodendrogliomas are located in the cerebral hemispheres and typically originate in white matter with secondary invasion of the cortex. They occur infrequently in the cerebellum, brain stem, and spinal cord. Occasional mitosis and a Ki-67/MIB-1 labeling index of up to 5% are compatible with WHO grade II oligodendroglioma. While there are no immunohistochemical markers specific for these tumors, they do share several genetic similarities. Moreover, 80% bear the molecular hallmark of combined loss of 1p and 19q (Kraus et al., 1995) , as well as somatic IDH1 mutations. In contrast, TP53 mutations are encountered in only 5% of oligodendrogliomas (Balss et al., 2008) .
Ependymomas are composed of cells with regular round or ovular nuclei and a variably dense fibrillary background. Tumor cells may form gland-like round or elongated structures that resemble the embryologic ependymal canal, with long, delicate processes extending into the lumen. More frequently, ependymomas are found with perivascular pseudorosettes in which tumor cells are arranged around vessels with an intervening zone consisting of thin ependymal processes directed toward the walls of the vessel (Cotran et al., 2005) .
Some studies identified the following genetic defects: a loss of loci on chromosome 22; mutation of p53 (in malignant ependymoma) (Metzger et al., 1991) ; a recurring breakpoint at 11q13 (Sainati et al., 1992) ; abnormal karyotypes with frequent involvement of chromosome 6 and/or 16 (Mazewski et al., 1999) ; and NF2 mutations. The clustering of ependymomas has been reported in some families; in one family, segregation analysis suggested the presence of an ependymoma tumor suppressor gene in the region of the chromosome 22 locus loss (22pter-22q11.2) (James et al., 1990; Nijssen et al., 1994; Ebert et al., 1999; Hulsebos et al., 1999; Yokota et al., 2003) .Histologically, oligodendroglial and ependymal neoplasms form a continuous spectrum ranging from well differentiated to anaplastic tumors. Different classification systems based on various morphological criteria have been used for grading these lesions (Kernohan et al., 1949; Smith et al., 1983; Shaw et al., 1992; Kleihues et al., 1993; Kros et al., 1994) . However, there has been no single reliable histological feature, so most studies have suggested the use of a combination of histological findings to identify the more aggressive tumors.
These histopathological features include signs of anaplasia such as increased cellularity, cellular pleomorphism, nuclear atypia, and high mitotic activity. Microvascular proliferation or necrosis may also be present. The application of histological criteria for the correct diagnosis and grading of individual tumors is relatively subjective, and there is often a lack of reproducibility among observers. Although the histological diagnosis of oligodendrogliomas and low-grade gliomas can be generally simple, morphological classification is often ambiguous and would be facilitated by specific subtype markers.
Meanwhile, gene expression profiling is becoming an established method to characterize cancer types and has been extensively used to analyze glioblastomas and to compare low-grade gliomas and glioblastomas. More recently, cDNA and oligonucleotide microarray techniques have been used to establish gene expression patterns of astrocytic tumors and oligodendrogliomas with different histological grades (Fuller et al., 1999; Huang et al., 2000; Sallinen et al., 2000; Markert et al., 2001; Watson et al., 2001; Mukasa et al., 2002) . Huang et al. (2004) directly compared low-grade oligodendrogliomas and astrocytomas. This cDNA array analysis was used to identify a number of genes that are differentially expressed in oligodendrogliomas and low-grade, diffuse astrocytomas (Huang et al., 2004) . However, a direct comparison between low-grade oligodendrogliomas and ependymomas has not previously been published.
In the present study, we first performed gene expression profiling for 5 oligodendrogliomas (WHO grade II) and 4 ependymomas (WHO grade II) using an Affymetrix oligo array (Affymetrix human 133plus 2.0) with 54,676 probe IDs. Hierarchical clustering (HCL), principal component analysis (PCA) and prediction analysis of microarrays (PAM) (Tibshirani et al., 2002) analyses were employed to test whether ependymomas and oligodendrogliomas could be separated in accordance with their gene expression patterns and whether subgroups within a histologic type could be identified.
MATERIALS AND METHODS
Thirteen human pathologic tissue specimens (five grade II oligodendrogliomas, four grade II ependymomas and four normal brain tissue samples) were obtained from resected tissues in the Neurosurgery Department of Shanghai Changzheng Hospital (Shanghai, China) between 2004 and 2006. The normal brain control samples were obtained from overlying cortex during routine resection of deep inter-cerebral metastases. All protocols and consent forms were approved by the hospital's institutional review board and informed consent was obtained from all patients. Before RNA extraction was performed, the pathological diagnoses of the specimens were confirmed by two senior clinic-pathologists, Fulin Zhang and Yichang Yu, from the Department of Pathology, Huashan Hospital, Fu Dan University (Shanghai, China). Specimens were flash-frozen in liquid nitrogen and stored at -80C. Table 1 shows the histological characteristics and clinical disease stage of the tumor samples (four grade II ependymomas, five grade II oligodendrogliomas, as well as one pooled and three additional normal samples).
Extraction of RNA
RNA was extracted using Trizol reagent and further purified using the Qiagen RNeasy Mini Kit (Catalog No: 74104) following the manufacturer's (Qiagen, Hilen, Germany) instructions. RNA quality was assessed by formal dehyde denaturing agarose gel Samples were hybridized to the Affymetrix Human Genome U133 Plus2.0 GeneChip arrays following the manufacturer's protocols. The arrays were scanned using a GeneChip Scanner 3000. The resulting images were processed using GeneChip Operating software (GCOS v1.3), and the CEL files were used for further analysis. The raw data were deposited in the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/projects/geo/query/acc.cgi?ac c=GSE21354) with accession number GSE21354.
Gene expression profiling
Raw CEL files were imported into the statistical software R (v2.12.1.) (R_Development_Core_Team, 2006) using Bioconductor (v2.7.6) . After installing two key packages, hgu133plus2cdf (v.2.5.0) and hgu133plus2probe (v.2.5.0), affy (v.1.24.2) and simpleaffy (v.2.22.0) were used for quality control tests of the Affymetrix arrays (Affymetrix Hu133plus2.0). RNA degradation was assessed using the function AffyRNAdeg from the affy package. We verified that the array data passed quality control tests (Supplementary Figure 1) , and then we normalized the raw data using the package gcRMA (Wu et al., 2004) . The "affinities" model of gcRMA, which uses mismatch probes as negative control probes was used to estimate the non-specific binding of probe sequences. The normalized values of expression are in log2 scale to attenuate the effect of the outliers. The presence/absence calls provided a statistical measure of the presence of a transcript within the tested biological sample. Details of the calculations can be found in the Affymetrix Microarray Suite User Guide (Affymetrix, 2001) (http://www.affymetrix.com/support/technical/manuals.affx). Moreover, for the absolute detection of transcripts (presence or absence calls), we used a method (Schuster et al., 2007) that replaces all mismatch (MM) probe values with a threshold value that is based on the mean perfect match (PM) value (after gcRMA transformation) of the probe sets that are unlikely to match target transcripts. This removes the influence of probe sequence affinity and results in better performance than the MAS 5 algorithm (Roux and Robinson-Rechavi, 2008 ). In the current study, the command mas5calls of Bioconductor was used to generate MAS 5.0 present/ medium/absent (P/M/A) calls. Presence/absence calls in the resulting output were extracted and mapped to expression values produced using gcRMA (McClintick and Edenberg, 2006) . We saved the normalized expression values from gcRMA performances in a matrix with the corresponding P/M/A values. This matrix was processed with TIGR MeV v4-6-01 (http://www.tm4.org/) (Saeed et al., 2003) . To filter these data using the MeV operation platform, we first removed a set of quality control probes, and then created a matrix composed of each probe ID, its corresponding sample expression value, and its CALL (CALL: P, present; A, absent, M, medium). The following formula was used to exclude redundant probes:
Where, N(P), N(A) and N(M) stand for the number of P, A and M, respectively. If the value was less than 10%, the corresponding probe ID would be excluded. Briefly, probes with P / (P + M + A) values less than 10% were removed.
Data analysis
Currently, one-way analysis of variance (ANOVA) is implemented in the TIGR MeV (V 4-6-01) software tool. The user is initially required to enter the number of groups. In our study, this number was set to 3 (ACMs II, III, IV and controls). We then fit the one-way ANOVA models with separate means for each of the four groups. A standard Bonferroni correction was calculated for each gene. A gene is considered to be significant if the p-value associated with its standard Bonferroni correction is smaller than the critical p-value (0.01). Currently, pvalues are computed using only the standard Bonferroni correction and we performed this correction for each of the null hypotheses (the mean average intensities of the four groups were equal). The alternative hypothesis was that at least one mean was different. After one-way ANOVA processing, the significant probe sets (saved as a new data source) were analyzed by HCL in TIGR MeV as well as principal component analysis (PCA) (Pearson, 1901) , which used the R function prcomp (…, scale=TRUE) of Bioconductor v.2.2. HCL was performed using the Euclidean distance and average linkage algorithms.
We also performed unsupervised data mining, including HCL, for all data mining algorithms. In contrast, we chose prediction analysis of microarrays (PAM) (Tibshirani et al, 2002) for sample class prediction using the supervised mining method. Using 10-fold cross-validation, the filtered datasets were separated into a learning dataset (consisting of two normal samples, three grade II oligodendrogliomas and two grade II ependymomas) and a test dataset consisting of two normal samples, two grade II oligodendrogliomas and two grade II ependymomas. One-way ANOVA tests defined the significant probes using TIGR MeV (v.4-6-01) with the same parameter settings as described above. The significant probes exported from TIGR MeV were used for class prediction with 10-fold cross-validation using the PAM for excel package (www-stat.stanford.edu/~tibs/PAM/) (v.2.212) (Tibshirani et al., 2002) . Using PAM with a threshold (Δ) of 5.0, we built a classifier composed of 768 probes that resulted in "zero" misclassification error.
This classifier was applied to the test matrix data described above, consisting of the significant probes and their corresponding expression values.
RESULTS AND DISCUSSION
We analyzed the gene expression of five grade II oligodendrogliomas, four grade II ependymomas and four normal tissue specimens using Affymetrix HU-133PLUS 2.0 GeneChip microarrays with 54,676 probe IDs. Quality control tests on the normalized raw data measured the RNA degradation and control gene expression and we also calculated scaling factors, the percentage of genes present and the average background levels. All arrays showed acceptable quality control outcomes, including acceptable RNA degradation levels as shown in Supplementary Figure 1. 
HCL and PCA results
One-way ANOVA analysis of gcRMA-normalized data (from the 37,023 probes that passed quality control filters) left 1075 probes for PCA, HCL and class prediction analysis. The dendrogram and heat map ( Figures 1A and B ) from hierarchal clustering, as well as the two and three principal components from the PCA (Figures 1C and D) illustrate that all samples can be almost perfectly separated into three groups (that is; grade II ependymomas, grade II oligodendrogliomas and normal tissue). We used HCL and PCA algorithms to study the changes in the ependymomas and oligodendrogliomas on a genome-wide level (Figure 1) . In Figure  1A , each row represents the expression levels of a particular gene across all samples, and each column represents the expression level of all of the genes tested for each sample. This analysis showed that normal tissue and oligodendrogliomas grouped into one branch with two sub-branches, one for oligodendrogliomas and another for normal tissue. This shared grouping was separate from ependymoma clusters.These data show that genome-wide transcript profiling can be used to distinguish the two types of grade II gliomas from normal tissue. They also indicate that there is a distinct molecular profile among tumors within a particular clinical classification ( Figures 1A and B) . PCA is a linear projection method that reduces the complex dimensionality of microarray data to create a three-dimensional plot to visualize the relatedness of the tumors. We used the first two and three principal components to test whether the above subsets could be used to distinguish grade II oligodendrogliomas, grade II ependymomas, and normal brain samples ( Figures 1C and D) . This analysis showed a clear separation of all three groups based on the sample genes. Thus, both HCL and PCA tests indicate that genome-wide expression analysis can distinguish between these two types of glioma.
PAM classification
We performed a supervised analysis using "Nearest Shrunken Centroid Classifier" and the PAM for Excel package (v.2.212). Using a threshold (∆) setting of 5.0, we built a classifier containing 768 genes that yielded a misclassification error of 0. We then tested whether this classifier could distinguish between the two tumors subtypes and the two normal samples used in this study. As shown in Figure 2 , the two ependymomas could be correctly grouped with 100% certainty, whereas the oligodendroglioma and normal tissues could only be grouped with 50% certainty. Stated differently, the grade II ependymomas can be distinguished from both the normal tissue and grade II oligodendrogliomas, but the normal tissue and grade II oligodendrogliomas may not be precisely separated from each other based on the aforementioned 768 gene signatures. Thus, the result of the PAM classification is in agreement with that of HCL clustering. As expected, the two WHO grade II gliomas, the grade II oligodendrogliomas and the grade II ependymomas could be classified into one group that was distinct from the normal tissues using both classification and clustering algorithms (the supervised and unsupervised mining methods, respectively). However, Figures 1 and 2 demonstrate that while normal tissue and oligodendrogliomas were assigned to a single branch, ependymomas were grouped separately. This result seems inconsistent with the clinical diagnoses. However, in the report of Huang et al. (2004) , normal tissues and grade II oligodendrogliomas were also grouped into one cluster following the cDNA expression profiling. Our results agree with those of Huang et al. (2004) . In both studies, all normal tissue samples were individually derived from non-neoplastic accidental deaths. This eliminates possibility that the inability of gene expression profiling to distinguish Estimated probabilities for the test data. Epend, normal and OD denote grade II ependymoma, normal brain tissue and grade II oligodendrogliomas, respectively. The two ependymomas can be correctly grouped with 100% certainty, whereas, the certainty that the normal tissues and oligodendrogliomas are correctly classified is 50% for both samples.
oligodendroglioma from normal tissue may be due to these diffusely infiltrative tumors permeating the underlying brain parenchyma, which can cause traces of oligoden-drogliomas to present in both tumor and normal samples. On the other hand, recent studies have found that the malignancy of grade II ependymomas is worse than that of grade II oligodendrogliomas from a gene expression perspective. According to clinical surveys, approximately 66 to 78% of people diagnosed with grade II oligodendroglioma live for at least 5 years. However, only 50% of people diagnosed with grade II ependymomas live for at least 5 years. Furthermore, 30 to 38% of people diagnosed with grade III oligodendroglioma will live for at least 5 years, while people with high-grade epen-dymomas will, on average, survive only 2 to 3 years (CancerHelp UK, 2010) . Therefore, our research may help develop molecular tests that improve clinical diagnoses to distinguish between oligodendrogliomas and ependymomas. Moreover, to find genetic markers that distinguish between these two kinds of gliomas (grade II ependymomas and grade II oligoden-drogliomas), we used PAM to further list genes with a lower threshold of 5.0 in the Excel package, and eventually, the 53 most differentially expressed genes (listed in Table 2 ) may present as markers to differentiate grade II ependymoma from grade II oligodendrogliomas.
Conclusion
While there is an abundance of studies of gene expression profiles from gliomas, few have been recently published that aim to detect molecular markers that distinguish grade II ependymomas from oligodendrogliomas. In our study, the nearest shrunken centroid model was successful in finding genes that predict the gliomas class. This method found a set of 53 genes that may potentially differentiate grade II ependymomas from grade II oligodendrogliomas. The success of our methodology has implications for improving the diagnosis of cancer. The method efficiently uncovers and ranks genes that are capable of distinguishing one type of tumor from another. Ultimately, this technique may be used to search for genes that are predictive for chemotherapy responsiveness profiles. For the two grade II gliomas, the predictive genes are attractive candidates for raising antibodies suitable for immunostaining.
Immunohistochemistry has an advantage for analyzing difficult specimens because it allows the pathologist to localize the stain to the tumor cells. In addition, our results suggest that RNA-based diagnostic tests may soon become feasible, based on either small-scale microarrays or quantitative PCR.
Regarding this genome-wide microarray expression level analysis, we are the first to report that the classification of the two grade II gliomas (grade II ependymomas and grade II oligodendrogliomas) by gene expression using HCL, PCA and PAM, which is almost completely in agreement with previously established clinical pathologic stages. This study therefore sets the stage for the further discovery of basic mechanisms that underlie a diseased state of astrocytoma and will be useful in targeting genes for diagnosis, prognosis and therapeutic intervention. It also provides a novel global view of the differences between grade II oligoden- 
